FDX1 as a novel biomarker and treatment target for stomach adenocarcinoma

Table 1 Patient Characteristics of individuals with stomach adenocarcinoma in The Cancer Genome Atlas datasets, n (%)

Characteristic	Levels	Overall (n = 375)
T stage	T1	19 (5.2)
	T2	80 (21.8)
	T3	168 (45.8)
	T4	100 (27.2)
N stage	N0	111 (31.1)
	N1	97 (27.2)
	N2	75 (21)
	N3	74 (20.7)
M stage	M0	330 (93)
	M1	25 (7)
Pathologic stage	Stage I	53 (15.1)
	Stage II	111 (31.5)
	Stage III	150 (42.6)
	Stage IV	38 (10.8)
Gender	Female	134 (35.7)
	Male	241 (64.3)
Age	≤ 65	164 (44.2)
	> 65	207 (55.8)
OS event	Alive	228 (60.8)
	Dead	147 (39.2)
DSS event	Alive	263 (74.3)
	Dead	91 (25.7)
PFI event	Alive	251 (66.9)
	Dead	124 (33.1)
Age, median (IQR)		67 (58, 73)

OS: Overall survival; DSS: Disease-specific survival; PFI: Progression-free interval.